Lead Therapeutic

ADC CM-09 Kills TRA-1-60 Positive Cancer Cells

CM-09 is a human chimeric IgG1 monoclonal antibody, of *CM-14, with a cleavable peptide linker (MC-Val-Cit-PAB) and an anti-mitotic payload MMAE (Monomethyl auristatin E). Linker and payload were used in the first FDA-approved ADC, Adcetris by Seattle Genetics. Cancer cells are killed with the TRA-1-60 cancer target dose-dependent but does not affect TRA-1-60 negative cells. CM-09 has been validated in vitro as a potent and selective cancer drug candidate.

*CM-14 is a highly stable and efficient ADC humanized into Bstrazumab, a monoclonal antibody with a Mono-Methyl Auristatin E / valine-citrulline dipeptide linker.

  • There are no meaningful or effective treatments for patients with metastatic colon, gastric, and
    pancreatic cancers.

  • The cancer-specific target TRA-1-60 presents a strong clinical opportunity for a targeted therapeutic
    approach with CM-14.

    • The safety profile of CM-14 is expected to be excellent since the target is not in normal tissues.

  • Pre-clinical data validate the potential of CM-14, to successfully treat aggressive forms of cancer
    for which there is currently a high mortality rate and a high unmet need for new therapies.

CM-09 is a Potent Drug in Human Cancer Mouse Models

  • Mice were implanted with TRA-1-60, filled with positive human embryonal carcinoma cells (NCCIT), and treated with control drugs (Iso-control IgG1, Saline) or CM-09.

  • CM-09 has been validated in vivo as a cancer drug candidate.

  • The graph shows tumor volume 40 days after starting the treatments. CM-09 inhibits tumor growth in a target-dependent manner in the carcinoma xenograft mouse model.

CM-09 Activity in Gastric Cancer In Vivo PDX Models

CM-09 with the MMAE payload (antimitotic mechanism) and
CM-ACD3 with the payload
(DNA-alkylating mechanism)
both show compelling and significant activity in human gastric cancer mouse PDX models